Latest news with #Harr
Yahoo
4 days ago
- Business
- Yahoo
Davison County board, sheriff discuss long-term need for a new county jail
May 30—MITCHELL — While talk about a potential state prison outside of Mitchell has gotten more attention, Davison County leaders have said their own "worst in the state" corrections facility needs replacement soon. The topic was a discussion item on May 27 as the commissioners went through the county sheriff's 2026 budget. "It's not uncommon to see pieces of concrete coming off of walls," Davison County Sheriff Steve Harr said. "We're very well known in South Dakota amongst law enforcement and inmates that we have the worst jail in South Dakota. It's seen its day." The current facility is located at 1015 S. Miller Ave., one that the county has used for a jail for nearly 30 years. The county purchased the former Methodist hospital in the early 1990s and repurposed a portion of it move the jail from the Davison County Courthouse in 1996. Other elements of the building date back further and the county has had to regularly update the building's mechanical equipment in recent years to keep the building operational. The jail has a maximum capacity of 72 inmates but Harr said the realistic capacity is closer to 60 inmates at once. The current Davison County facility has one big positive that the county doesn't want to lose. It has the sheriff's office, jail and courtroom facilities all in one building, which makes transportation of inmates much easier and the overall administration of courts and corrections move smoothly. "It's going to be an expensive project when we get to it," Harr said. "Expensive probably isn't the right word for it." Harr said he's received a standing offer from Minnehaha County to tour their corrections facility, which was expanded in 2020 to add 320 inmate beds to bring the total to more than 700. Harr would like the commissioners to see the Lawrence County facility near Deadwood, which was completed earlier this year and took more than two years to complete. The commissioners discussed taking a potential field trip to the current Davison County Jail and to Sioux Falls around upcoming meetings to learn more about its needs. Harr said one potential plan to help fund the new facility would be to accept federal inmates. That's something the county can't currently do because it doesn't have the space. A site south of Mitchell is among the possible sites being discussed by a state panel that is looking at building a new state prison, with Mitchell offering the land last month. The commissioners, in a previous meeting, were supportive of that idea , although their own jail needs would almost certainly require a separate project. "I'm still pro getting a prison and putting a little lean-to (building) on it for the county," Commissioner Chris Nebelsick joked about the two potential projects. Commissioner John Claggett said he hopes the county project would be less than the Mitchell High School project, which is nearly $70 million and will be completed later this year. "It won't be," Commissioner Denny Kiner said of Claggett's price hopes being low. "The problem is we're doing a new school, we're spending $15 million on the lake and everyone is just spent right now," Nebelsick said. "And people are going to be asking about a jail but I'm out in the public telling everyone I see that we need a new jail. Anybody that knows me knows me, knows we need a jail and knows why." Harr said a potential collaboration with the city of Mitchell on a new public safety building should also be considered, he said, with a city-county partnership that has become increasingly more frequent in communities in South Dakota and around the Midwest. "It's probably a conversation to have with the city, as well, to have one modern facility rather than two rundown buildings," Harr said.
Business Wire
20-05-2025
- Business
- Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sana Biotechnology, Inc. ('Sana' or the 'Company') (NASDAQ: SANA) and reminds investors of the May 20, 2025, deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (2) SC291 in oncology, SC379, and SG299 were less promising than Defendants had led investors to believe; (3) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount; (4) accordingly, Defendants overstated Sana's financial capacity to maintain its current operations and advance its existing product candidates; and (5) as a result, Defendants' public statements were materially false and/or misleading at all relevant times. On October 10, 2023, during after-market hours, Sana issued a press release announcing that it "will reduce near-term spend on its fusogen platform for in vivo gene delivery" and instead "[i]ncreas[e its] focus on [its] ex vivo cell therapy platform[,]" thereby "postpon[ing] the planned SG299 IND" while "decreas[ing] its expected forward operating burn." Sana further disclosed a "29% headcount reduction" that, in tandem with the "decreased expenses related to the fusogen platform[,]" would keep its "2024 operating cash burn . . . below $200 million[,]" thereby "allowing [its] current cash position to extend further into 2025." The same press release also quoted Defendant Steven D. Harr ("Harr"), Sana's President and Chief Executive Officer, as stating that "[w]e need to ensure that we have a financeable cost structure with . . . emerging opportunities factored in," and that "this strategic re-positioning enables us to deliver significant clinical data across multiple drug candidates with the current balance sheet." On this news, Sana's stock price fell $0.34 per share, or 8.95%, to close at $3.46 per share on October 11, 2023. Then, on November 4, 2024, during after-market hours, Sana issued a press release announcing that it "will suspend development of both SC291 in oncology and of SC379 . . . as it seeks partnerships for these programs" and instead "increase its investment in its type 1 diabetes program with the cash savings from these changes[,]" thereby "extend[ing] its expected cash runway into 2026." The same press release also quoted Defendant Harr as stating that "we need to ensure that we are directing our investments into the areas where we believe we can have the greatest impact for patients" and that "[t]his modified strategy will also help us reduce our cash burn but comes with the necessity of parting with some talented and valued colleagues." On this news, Sana's stock price fell $0.37 per share, or 9.84%, to close at $3.39 per share on November 5, 2024. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Sana's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Sana Biotechnology class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
